The pharma world can be cutthroat as firms jockey for position with competing drugs. But even in that context, Pfizer's decision to announce a late-November launch of its competing version of Johnson & Johnson's best-selling drug Remicade the afternoon before J&J released its third-quarter earnings seems a bit cold. Pfizer's announcement cast a shadow on another blockbuster quarter from J&J, whose shares fell 2.7 percent on Tuesday. But J&J isn't going to let Remicade's $6.5 billion in sales slip gently into the good night. And it's better positioned than just about any other company to weather such a storm. Pfizer's drug, Inflectra, is not your standard generic. J&J's drug Remicade is what's known as a biologic drug, made with living cells instead of a chemical process. It's impossible to copy exactly; hence the term "biosimilar." The regulatory tango involved in getting such a drug approved is about as complicated as making it. Inflectra is just the second biosimilar to hit the U.S. market.

It's going to be a huge test of how willing doctors are to prescribe biosimilars, how aggressive payers will be in pushing them, and how firms will fight for biologic market share over the next decade. Remicade sales helped Johnson & Johnson top earnings estimates in the latest quarter. Sales of the drug grew more than 10 percent from a year ago -- but such performance likely won't be seen again.Merck markets the drug in Europe and splits the profits with Johnson & Johnson. Biosimilars first launched in that region in February of last year, and Merck saw sales drop by more than $500 million compared to 2014, a substantially bigger decline than what analysts currently expect for J&J in 2017.desmond miles cosplay costume hoodie Things are a bit more complicated in the U.S.Pfizer's drug is an "at risk" launch; bape shark hoodie for sale

there are still outstanding patent appeals that could tangle things up. The FDA has yet to release guidance that would make it easier for pharmacists to switch patients from Remicade to Inflectra. Pfizer is also pricing its drug at a relatively modest 15 percent discount, which may help J&J minimize the sales impact. The J&J company line, per its earnings call, is that it already faces biosimilar competition elsewhere and has managed to preserve most of its market share. It argues doctors and patients will be reluctant to switch and expects only a "modest" impact from Pfizer's launch.  jinx hoodie youthRemicade sales will drop -- possibly more than expected, if it loses major market share or payers press J&J for discounts. lady sovereign hoodiesThat means J&J must rely on its pipeline for future growth -- but there are worse things.

Last year, J&J committed to file for regulatory approval for a total of 10 drugs with at least $1 billion peak sales potential each by 2019. One of those, the cancer drug Darzalex, has already been approved.By 2019, the company also expects to file for 10 line extensions -- expanded approvals for existing drugs -- that it says could account for at least $500 million each in peak sales. If even a modest portion of that forecast is met, then Remicade becomes much less of a worry.Though J&J's device and consumer businesses are declining in relative importance, they still combined to deliver $9.4 billion in sales in the quarter and give the company a steady base other competing pharma firms lack. That makes J&J less dependent on Remicade.Yes, the drug accounted for 21 percent of pharmaceutical sales in the latest quarter. But it provided only 10 percent of J&J's total sales. Contrast that with AbbVie, whose biosimilar-threatened blockbuster Humira accounted for 64 percent of revenue in the second quarter. 

If that's not enough, J&J also has $42.5 billion in cash on hand and is on the hunt for pharma acquisitions. It's on its way to more than $72 billion in revenue in 2016 and delivers on or exceeds expectations quarter after quarter. If Pfizer wants to truly rattle J&J, it may have to try a bit harder. This column does not necessarily reflect the opinion of Bloomberg LP and its owners. To contact the author of this story: Max Nisen in New York at mnisen@bloomberg.netTo contact the editor responsible for this story: Mark Gongloff at mgongloff1@bloomberg.net Martial Arts Equipment from Faze provides CE approved protective equipment for all styles of martial arts: Superb Premier Quality Clothing and Printing Taekwondo, Karate, Kung fu, Thai Boxing, Mixed martial Arts Kickboxing and many more unique and elite styles. Please contact us if you require any assistance in your choice of martial arts equipment. Martial Arts Equipment supplied by Faze martial arts.

Martial arts equipment, clothing, Printing Rema Leisure Ltd, 105 Jockey Road, Sutton Coldfield, West Midlands, B73 5PH Tel 0121 354 9520 Company number: 446 4281 V.A.T reg: 614 1433 79 Price (Low to High) Price (High to Low) Hh Distribution Llc Dba: Jslv Picture Organic Clothing Corp Swallows & Daggers Limited Obey Afton Burgundy Hoodie RipNDip Cats Navy Hoodie adidas Blackbird Navy, Maroon & White Hoodie Ninth Hall Discover Dirty Blush Hoodie Cookies Thin Mint High Density Heather Grey Hoodie Thrasher Flame Logo Forest Green Hoodie Obey Watson Black Hoodie Brixton Wheeler Grey Crew Neck Sweatshirt Primitive Sprinter Piped Navy, Heather Grey, & Burgundy Hoodie The Hundreds Canal Black, Blue & Grey Hoodie Thrasher Two Tone Black Hoodie Empyre Business Blue Crew Neck Sweatshirt Thrasher Flame Logo Hoodie adidas Clima 3.0 Black Hoodie RipNDip Catstanza Mint Pullover Hoodie

Odd Future Donut Logo Hoodie RipNDip Get Outer Here Light Pink Hoodie Obey New Times Propaganda Dusty Light Army Green Hoodie RipNDip We Out Here Black Hoodie Sketchy Tank Flipout White Hoodie Thrasher Silver Flame Logo Grey Tie Dye Pullover Hoodie Empyre Baseline Embroidered Khaki Hoodie Carhartt Midweight Heather Grey Crew Neck Sweatshirt Obey New Times Black & Grey Hoodie HUF Worldwide Black Hoodie Empyre Deadhead Bright Tie Dye Hoodie Empyre Ocean Floor Pink Tie Dye Hoodie The Hundreds Forever Slant Black Pullover Hoodie 40s & Shorties Ice Cream Pink Hoodie Naketano Supapimmel VII Green Melange Hoodie Naketano Diese Nusse VI Dark Blue Hoodie Obey Spider Rose Black Hoodie Sketchy Tank Roses Black Hoodie Primitive A-Frame Green Hoodie Ninth Hall Lower Lights Denim Blue Wash Hoodie Crooks & Castles Parker Rifle Green Hoodie Thrasher Skate Mag Radical Red Pullover Hoodie Diamond Supply Co OG Sign Hoodie